Brief: Avacta Therapeutics Says Ava6000 Phase 1 Trial Showed Tumor Shrinkage In Salivary Gland Cancer Patients

Avacta

16/01/2025 12:05

Jan 16 (Reuters) - Avacta Therapeutics  AVCT.L :
    * AVACTA THERAPEUTICS: AVA6000 PHASE 1 TRIAL SHOWED
CLINICALLY
MEANINGFUL TUMOR SHRINKAGE IN PATIENTS WITH SALIVARY GLAND
CANCERS
    * AVACTA THERAPEUTICS: PHASE 1B EXPANSION COHORTS SCREENING
PATIENTS IN TRIPLE NEGATIVE BREAST CANCER, SOFT TISSUE SARCOMA
AND SALIVARY GLAND CANCER

Source text:  ID:nGNX4lG4Dm 
Further company coverage:  AVCT.L 

 ((Reuters.Briefs@thomsonreuters.com;))